Introducing mods: A low-cost, low-tech tool for high-performance detection of tuberculosis and multidrug resistant tuberculosis

Introducing MODS: a low-cost, low-tech tool for high-performance detection of tuberculosis and multidrug resistant tuberculosis.

*Corresponding author (email: ) Imperial College London Wellcome Trust Centre for Clinical Tropical Medicine (LC) and Laboratorio de Investigación de Enfermedades Infecciosas (DAJM), Universidad Peruana Cayetano Heredia, Av. Honorio Delgado No 430, Urb. Ingeniería, Perú Received : 09-11-06 Accepted : 21-11-06 The urgent need for improved diagnostic tools for detection of t...

Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis

Introduction: The incidence of multidrug resistant tuberculosis is increasing in developing countries. Aminoglycosides are an integral part of second-line drugs, however ototoxicity is a major limitation for their use. This study aims to determine the extent of hearing loss in patients taking one of the commonly prescribed drugs for Multidrug resistant tuberculosis (MDR-TB), Kanamycin, at a Gov...

Rapid Tests for Multidrug Resistant Tuberculosis in Low Income Settings

Multidrug-resistant Tuberculosis Detection, Latvia

To improve multidrug-resistant tuberculosis (MDR-TB) detection, we successfully introduced the rpoB gene mutation line probe assay into the national laboratory in Latvia, a country with epidemic MDR-TB. The assay detected rifampin resistance with 91% sensitivity and 96% specificity within 1 to 5 days (vs. 12-47 days for BACTEC).

Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis

BACKGROUND Despite the existence of effective drug treatments, tuberculosis (TB) causes 2 million deaths annually worldwide. Effective treatment is complicated by multidrug-resistant TB (MDR TB) strains that respond only to second-line drugs. We projected the health benefits and cost-effectiveness of using drug susceptibility testing and second-line drugs in a lower-middle-income setting with h...